Filing Analysis
Securities Offering
Filed Mar 16, 2026
MEDIUM
Elicio Therapeutics has established a new $100 million at-the-market (ATM) equity offering program and terminated its existing $40 million ATM facility.
Red Flags
- Potential for significant shareholder dilution totaling up to $100 million
- Substantial increase in the size of the ATM facility from $40 million to $100 million may indicate high future capital requirements
Key Facts
- Entered into an At Market Issuance Sales Agreement for up to $100.0 million in common stock on March 16, 2026
- Agents for the new offering are B. Riley Securities, JonesTrading, and Ladenburg Thalmann
- The company will pay a 3.0% commission on gross sales proceeds
- Terminated a prior $40.0 million Sales Agreement with JonesTrading originally entered into on June 3, 2024
- The offering is conducted via a registration statement on Form S-3 (File No. 333-293861)
Regulation FD Disclosure
Filed Mar 12, 2026
LOW
Elicio Therapeutics announced its financial results for the full year ended December 31, 2025, and provided corporate updates via a press release on March 12, 2026.
Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The announcement was made on March 12, 2026, via a press release furnished as Exhibit 99.1.
- The report includes corporate updates alongside the financial data.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.